EuMentis Therapeutics

Eumentis is a development stage biotech focused on developing it's lead molecule EM-036, a 2nd-Gen NMDAR antagonist for the treatment of Autism-spectrum disorders and Alzheimer's Disease. The company is currently raising $3-5M in a seed round to complete IND enabling studies, file its IND, manufacture CTM and complete Phase I clinical trials. Exit will be trade sale or IPO upon reaching P2 clinical POC.